Orismilast may improve hidradenitis suppurativa with dose-dependent tolerability

Orismilast may improve mild to severe hidradenitis suppurativa; however, further studies are needed to confirm patient tolerability in this indication, according to a study.
“Phosphodiesterase-4 (PDE4) inhibition is promising for the treatment of chronic inflammatory diseases,” Camilla G. Frederiksen, MD, of the department of dermatology at Zealand University Hospital in Denmark, and colleagues wrote. “Inhibition of PDE4B/D subtypes drives the anti-inflammatory effects of PDE4 inhibitors in immune cells and impact the production of pro-inflammatory cytokines.”

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart